Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of isolates collected in Dakar in 2013 to 2015 showed -reduced susceptibility to piperaquine. Neither the exonuclease E415G mutation nor the copy number variation of the gene (), associated with piperaquine resistance in Cambodia, was detected in Senegalese parasites.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496083PMC
http://dx.doi.org/10.1128/AAC.02445-18DOI Listing

Publication Analysis

Top Keywords

baseline molecular
4
molecular responses
4
responses plasmodium
4
plasmodium falciparum
4
falciparum isolates
4
isolates piperaquine
4
piperaquine implementation
4
implementation dihydroartemisinin-piperaquine
4
dihydroartemisinin-piperaquine senegal
4
senegal dihydroartemisinin-piperaquine
4

Similar Publications

Vector-borne diseases pose a major worldwide health concern, impacting more than 1 billion people globally. Among various blood-feeding arthropods, mosquitoes stand out as the primary carriers of diseases significant in both medical and veterinary fields. Hence, comprehending their distinct role fulfilled by different mosquito types is crucial for efficiently addressing and enhancing control measures against mosquito-transmitted diseases.

View Article and Find Full Text PDF

Limited knowledge exists regarding biomarkers that predict treatment response in Lupus nephritis (LN). We aimed to identify potential molecular biomarkers to predict treatment response in patients with LN. We enrolled 66 patients with active LN who underwent renal biopsy upon enrollment.

View Article and Find Full Text PDF

The study aims to address the critical issue of toxic side effects resulting from drug combinations, which can significantly increase health risks, clinical complications, and lead to drug being withdrawn from the market. A model named TSEDDI (toxic side effects of drug-drug interaction) has been developed to improve the identification of drug pairs that may induce toxicity or adverse reactions. By utilizing drug chemical structures and diverse proteins, we employ a convolutional neural network (CNN) to extract features from molecular images, enzyme proteins, transporter proteins, and target proteins.

View Article and Find Full Text PDF

Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment.

Alzheimers Dement

December 2024

Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven, Belgium.

Introduction: The longitudinal progression of synaptic loss in Alzheimer's disease (AD) and how it is affected by tau pathology remains poorly understood.

Methods: Thirty patients with amnestic mild cognitive impairment (aMCI) and 26 healthy controls underwent cognitive evaluations and tau, synaptic vesicle protein 2A (SV2A), and amyloid positron emission tomography. Twenty-one aMCI underwent 2-year follow-up (FU) investigations.

View Article and Find Full Text PDF

Molecular biomarkers associated with TBI outcome in individuals of Black racial identity or African ancestry: a narrative review.

World Neurosurg

December 2024

College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA; Global Neurosurgery Laboratory, SUNY Downstate Health Sciences University, Brooklyn, New York, USA; Department of Neurology, One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn, New York, USA; Department of Neurology; SUNY Downstate Health Sciences University, Brooklyn, New York, USA; Institute for Genomics in Health, SUNY Downstate Health Sciences University, Brooklyn, New York, USA; Division of Neurosurgery, Department of Surgery, SUNY Downstate Health Sciences University, Brooklyn, New York, USA; Department of Community Health Sciences, School of Public Health, SUNY Downstate Health Sciences University; Department of Surgery, One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn, New York, USA. Electronic address:

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide and a major global health concern. In the United States (US), individuals of Black or African American racial identity experience disproportionately higher rates of TBI and suffer from worse post-injury outcomes. Contemporary research agendas have largely overlooked or excluded Black populations, resulting in the continued marginalization of Black patient populations in TBI studies, thereby limiting the generalizability of ongoing research to patients in the US and around the world.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!